PTO/SB/08s (08-03)
Approved for use through 97/31/2006, 0NE 0851-0231
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number. Application Number

Filing Date

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)					First Named Inventor Toshihide TSURATA									
						IIVEIIIOI	-							
					Art Unit									
				Examiner Name								_		
				Attorr	ney Doc	ket Numb	er	70404.9	90/ma					
					U.S.I	PATENTS					Remove			
Examiner Initial*	Cite No				Date	of cited Document					Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	5837614		1998-1	1-17	Yamazak	i et al.							
	2													
If you wish	h to a	dd additional U.S. Pate	nt citatio	n inform	nation pl	ease click	the A	dd butto	n.		Add			
_			U.S.P	ATENT	APPLIC	CATION P	UBLI	CATION	s		Remove			
Examiner Cite   Publication Number   Kind   Code1				Publication Name of Patentee or Applicant of cited Document Pages, Columns, Relevant Passag Figures Appear										
	1	20030109147		2003-0	6-12	Kim et al.								
If you wish	h to a	dd additional U.S. Pub	lished An	nlication	n citation	informati	on nic	assa click	r the Arl	d button	Add			
ii you misi		oo additonal o.o. i ab	iionicu / ip			ENT DO	•			u Dutto	Remove		_	
_				TORLE	OIL TAI	Livi Doc	1			-	Bassa Cal	umpo Lippo	_	
Examiner Initial*	Cite No					Publication Date	on /	Name of Patente Applicant of cited Document		e or	where Rel Passages	ges,Columns,Lines lere Relevant issages or Relevant gures Appear		
	1	06-302591	JP			1994-10-2	28						V	
	2	61-056415	JP			1986-03-2	22						<b>V</b>	

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT A ( Not for submission under 37 CFR 1.99) F

pplication Number		
iling Date		
irst Named Inventor	Tosh	hide TSUBATA
rt Unit		
xaminer Name		
ttomey Docket Numb	er	70404 90/ma

Date Considered

1

	3	04-099282	JP		1992-03-31			V	
	4	10-050998	JP		1996-02-20			Z	
	5	09-289210	JP		1997-11-04			V	
	6	2002-329869	JP		2002-11-15			V	
	7	2003-124469	JP		2003-04-25			Ø	
If you wish to add additional Foreign Patent Document citation information please click the Add button Add									

NON-PATENT LITERATURE DOCUMENTS Remove Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Examiner Cite Т5 (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), Initials\* No publisher, city and/or country where published.

International Search Report issued in the corresponding International Application No. PCT/JP2004/018051, dated

If you wish to add additional non-patent literature document citation information please click the Add button Add

FYAMINER SIGNATURE

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that assued the document, by the two-letter code (WIPO Standard ST 3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language translation is attached

1

Examiner Signature

March 8 2005

# Application Number Flang Date STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Application Number | Toubhide TSUBATA Art Unit Examiner Name | Examiner Name | Toubhide TSUBATA | Art Unit | Toubhide TSUBA

## CERTIFICATION STATEMENT

Diagra coo	27	CED	4	07	and	4	00	**	make the	_	appropriate selection(s):	

information disclosure statement. See 37 CFR 1.97(e)(1).

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the

# OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

## SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

ioni oi die signatale.											
Signature	/Peter Medley #56,125/	Date (YYYY-MM-DD)	2006-05-02								
Name/Print	Peter Medley	Registration Number	56125								

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S.231.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.231.1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2044 and 2046. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.